We are live on ! Find out more
TYRA icon

Tyra Biosciences
TYRA

116 hedge funds and large institutions have $778M invested in Tyra Biosciences in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 38 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

32,900% more call options, than puts

Call options by funds: $330K | Put options by funds: $1K

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

44% more capital invested

Capital invested by funds: $542M → $778M (+$237M)

5% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 38

2.2% less ownership

Funds ownership: 106.59% → 104.39% (-2.2%)

4% less funds holding

Funds holding: 121 → 116 (-5)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

Holders
116
Holders Change
-5
Holders Change %
-4.13%
% of All Funds
1.52%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.07%
New
9
Increased
40
Reduced
38
Closed
14
Calls
$330K
Puts
$1K
Net Calls
+$329K
Net Calls Change
+$328K

Top Buyers

1
CP
Caligan Partners
New York
+$5.78M
2
CC
Commodore Capital
New York
+$3.14M
3
EP
Eversept Partners
New York
+$3.11M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3M
5
BFM
Boothbay Fund Management
New York
+$2.13M

Top Sellers

1
O
OrbiMed
New York
-$7.7M
2
SCM
Sio Capital Management
New York
-$3.37M
3
BI
BVF Inc
California
-$3.36M
4
Millennium Management
Millennium Management
New York
-$3M
5
Bank of America
Bank of America
North Carolina
-$2.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$171M – – –
APMC
2
Alta Partners Management Company
Wyoming
$57.1M – – –
NI
3
Nextech Invest
Switzerland
$56.7M – – –
BI
4
BVF Inc
California
$51.1M -$3.36M -294,400 -7%
CPX
5
Canaan Partners XI
California
$50.5M – – –
CC
6
Commodore Capital
New York
$47.2M +$3.14M +275,000 +9%
TCM
7
TCG Crossover Management
California
$40.5M – – –
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$40.2M +$211K +18,514 +0.6%
VPC
9
Vestal Point Capital
New York
$33.9M -$2.62M -230,000 -9%
KCM
10
Kynam Capital Management
New Jersey
$32.6M – – –
BlackRock
11
BlackRock
New York
$26.2M -$272K -23,854 -1%
Vanguard Group
12
Vanguard Group
Pennsylvania
$21.3M +$1.35M +118,492 +8%
FCM
13
Farallon Capital Management
California
$16M – – –
5VM
14
5AM Venture Management
California
$13.1M – – –
Balyasny Asset Management
15
Balyasny Asset Management
Illinois
$11.8M +$3M +263,199 +45%
CP
16
Caligan Partners
New York
$9.75M +$5.78M +506,875 +267%
Marshall Wace
17
Marshall Wace
United Kingdom
$8.42M +$1.98M +173,907 +41%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$8.36M +$346K +30,328 +5%
SCM
19
Sio Capital Management
New York
$7.2M -$3.37M -295,327 -36%
State Street
20
State Street
Massachusetts
$5.99M +$108K +9,488 +2%
Morgan Stanley
21
Morgan Stanley
New York
$4.51M -$641K -56,259 -15%
Walleye Capital
22
Walleye Capital
New York
$4.17M -$828K -72,600 -20%
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$3.95M +$654K +57,332 +26%
EP
24
Eversept Partners
New York
$3.82M +$3.11M +272,706 New
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$3.52M -$1.64M -143,737 -36%
1
2 3 4 5

TYRA Hedge Fund Activity: Q3 2025 in Review

116 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q3 2025, worth a combined $778M — up 44% from $542M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of TYRA and 9 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 40 added.

The largest buyer was Caligan Partners, adding an estimated $5.78M. The largest seller was OrbiMed, exiting entirely with an estimated $7.7M sold.

  • 116 institutional investors held Tyra Biosciences (TYRA) as of Q3 2025, down from 121 in Q2 2025.
  • Funds reported $778M of Tyra Biosciences stock for Q3 2025, up 44% quarter-over-quarter.
  • 9 funds opened new Tyra Biosciences positions in Q3 2025 and 14 closed out, a net change of -5 holders.
  • The largest Tyra Biosciences buyer in Q3 2025 was Caligan Partners, an estimated $5.78M added.
  • The largest Tyra Biosciences seller in Q3 2025 was OrbiMed, an estimated $7.7M sold.

Based on aggregated 13F filings for Q3 2025.